Phase II trial of docetaxel for cholangiocarcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 1, 1999, Pages 78-81

  Pazdur, Richard ^a,c   Royce, Melanie E ^a   Rodriguez, Gladys I ^b   Rinaldi, David A ^b   Patt, Yehuda Z ^a   Hoff, Paulo M ^a   Burris, Howard A ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UT Health San Antonio   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cholangiocarcinoma; Docetaxel; Phase II study

Indexed keywords

DEXAMETHASONE; DOCETAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTIBIOTIC THERAPY; ARTICLE; BILE DUCT CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HUMAN; HYPOTENSION; INFUSION; MALE; MYALGIA; PHASE 2 CLINICAL TRIAL; SEPTIC SHOCK; STOMATITIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME;

EID: 0033508202     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199902000-00019     Document Type: Article

References (36)

1. Wanebo HJ, Ahlgren JD, Hill MC. Cancer of the biliary tract. In: Ahlgren JD, Macdonald JS, eds. Gastrointestinal oncology. Philadelphia: J B Lippincott, 1992:399-416.
2. Henson DE, Albores-Saavedra J, Cone D. Carcinoma of the extrahepatic bile ducts: histologic types, stage of disease, grade and survival rates. Cancer 1992;70:1498-501.
3. von Eyben F, Hellekant C, Mattson W, Ljungquist U, Jonsson K. Mitomycin-C in advanced gallbladder carcinoma. Acta Radiol Oncol 1980;19:81-4.
4. Crooke ST, Bradner WT. Mitomycin C: a review. Cancer Treat Rev 1976;3:121-39.
5. Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperative gall-bladder and bile duct cancer. Cancer 1984;54:965-9.
6. Davis HL, Ramirez G, Ansfield FJ. Adenocarcinoma of the stomach, pancreas, liver, and biliary tracts: survival of 328 patients treated with fluoropyrimidine therapy. Cancer 1974;33:193-7.
7. Harvey JH, Smith FP, Schein PS. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984;2:1245-8.
8. Hall SW, Benjamin RS, Murphy WK, Valdivieso M, Bodey GP. Adriamycin, BCNU, ftorafur chemotherapy of pancreatic and biliary tract cancer. Cancer 1979;44:2008-13.
9. Ravry MJR, Hester M. A phase II study of adriamycin plus bleomycin for the treatment of hepatocellular and biliary tract carcinoma [Abstract C-513]. Proceedings of the American Association of Cancer Research 1979;20:415.
10. Ringel I, Horowitz SB. Studies with taxotere (RP 58970): a semisynthetic analog of taxol. J Natl Cancer Inst 1991;83:288-97.
11. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP56976, NSC 628503), a taxol analogue. Cancer Res 1991;51:4845-52.
12. Rhone-Poulenc Rorer. Investigative Brochure on Docetaxel. Collegeville, PA: Rhone-Poulenc Rorer, Clinical Research Department, June 23, 1993.
13. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995;13:2643-55.
14. Piccart MJ, Gore M, Ten Bokkel Huinink W, et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995;87:676-81.
15. Hudis CA, Seidman AD, Crown JP, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:58-65.
16. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol 1996;14:1649-55.
17. Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993;11:950-8.
18. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989;10:1-10.
19. Ahlgren JD. Neoplasms of the hepatobiliary system. In: Calabresi P, Schein PS, eds. Medical oncology. 2nd ed. New York: McGraw-Hill, 1993:713-39.
20. Haskell CM, Lavey RS. Extrahepatic bile ducts. In: Haskell CM, ed. Cancer treatment. 4th ed. Philadelphia: W B Saunders 1995: 529-34.
21. Sali A, McQuillan T, Read A, Kune G. Rifampicin as cytotoxic agent for cholangiocarcinoma: preliminary report of seven cases. J Cancer Res Clin Oncol 1991;117:503-4.
22. Ellis PA, Norman A, Hill A, et al. Epirubicin, cisplatin and infusional 5-fluorouracil (ECF) in hepatobiliary tumours. Eur J Cancer 1995;31A:1594-8.
23. Zarba J, Rougier P, Armand JP, et al. Cisplatin and 5 day continuous infusion of 5-FU in treatment of metastatic biliary tract cancer: a phase II trial [Abstract 1297]. Proceedings of the American Association of Cancer Research 1992;33:1929.
24. Ajani JA, Ilson D, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86: 1086-91.
25. Ajani JA. Treatment of patients with upper gastrointestinal carcinomas. Semin Oncol 1997;24(suppl 19):72-6.
26. Ajani JA, Fairweather J, Dumas P, Pazdur R, Mansfield PF. A phase II study of taxol in patients with advanced untreated gastric carcinoma [Abstract 933]. Proceedings of the American Society of Clinical Oncology 1997;16:263a.
27. Brown T, Tangen C, Fleming T, Macdonald J. A phase II trial of taxol and granulocyte colony-stimulating factor (G-CSF) in patients with adenocarcinoma of the pancreas [Abstract 592]. Proceedings of the American Society of Clinical Oncology 1993;12: 200.
28. Einzig AI, Wiernik PH, Lipsitz AB, Benson AB. Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract: the Eastern Cooperative Oncology Group results [Abstract 566]. Proceedings of the American Society of Clinical Oncology 1993;12:194.
29. Ajani JA, Ilson DH, Kelsen DP. The activity of paclitaxel in gastrointestinal tumors. Semin Oncol 1995;22:46-50.
30. Sulkes A, Smyth J, Sessa C, et al. Docetaxel (taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC early clinical trials group. Br J Cancer 1994;70:380-3.
31. Verweij J, Catimel G, Sulkes A, et al. Phase II studies of docetaxel in the treatment of various solid tumours. EORTC early clinical trials group and the EORTC soft tissue and bone sarcoma group. Eur J Cancer 1995;31A(suppl 4):S21-4.
32. Kaye SB. Docetaxel (taxotere) in the treatment of solid tumors other than breast and lung cancer. Semin Oncol 1995;22(suppl 4):30-3.
33. Rougier P. Docetaxel delivers new management opportunities for gastrointestinal carcinomas. Anticancer Drugs 1995;6:525-9.
34. Pazdur R, Lassere Y, Soh LT, et al. Phase II trial of docetaxel (taxotere) in metastatic colorectal carcinoma. Ann Oncol 1994;5: 468-70.
35. Jones DV Jr, Lozano R, Hoque A, Markowitz A, Patt Y. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 1996;14:2306-10.
36. Pazdur R, Kudelka AP, Kavanagh J, et al. The taxoids: paclitaxel (taxol) and docetaxel (taxotere). Cancer Treat Rep 1993;19:351-86.